烟草在线据加拿大新闻报道编译　　全球卷烟制造商菲莫国际计划在加拿大疫苗开发商Medicago公司上投资1600万美元，收购49.9%的股份，成为控股股东。来源烟草在线

　　9月22日，这家位于魁北克城市通过类病毒颗粒接种的开发商说，私募配售收益将“将用于进一步为开发Medicago的流行病和季节性流行感冒疫苗提供资金。”来源烟草在线

　　9月中旬完成了以20亿美元收购加拿大烟草公司乐富门公司交易的菲莫国际，如果执行了所有的收买股票权意向的话，其对Medicago的持股将增加到58%。来源烟草在线

　　Medicago的首席执行官安迪·谢尔登（Andy Sheldon）在一次采访中说，大卷烟公司对加拿大小生物技术开发商的兴趣“实际上非常简单”。来源烟草在线

　　谢尔登说，菲莫“对烟草及烟草相关方面……农业经济学、生物技术、遗传学和所有方面有专业知识，” 同时，它正在卷烟之外寻找多样化。来源烟草在线

　　Medicago适合这一点，因为它是一家纯粹的健康护理公司，利用烟草“作为我们的机器，只要你愿意，生产出我们正在寻找的不同类型的疫苗，”他说。来源烟草在线

　　“所有我们要做的是改变烟草中基因的排列，来生产这些蛋白质。”来源烟草在线

　　根据9月22日宣布的无约束力的意向书，菲莫国际将购买4500万股，每股价格为35.5美分。来源烟草在线

　　谢尔登声称，投资表明了对公司所拥有的以植物为基础的技术平台的信心。来源烟草在线

　　“我们所做的真的是世界上独特的，”他说，提到Medicago已经设立了一个生产工厂，正努力使调整的疫苗得到批准。来源烟草在线

　　“这里有拥有烟草方面专业经验的公司就是菲莫国际，然后这里有另一家公司，就是Medicago，该公司开发出了一些独特的加拿大技术，能够快速而合算地生产疫苗。”来源烟草在线

　　此交易需要进行尽职调查，需要得到Medicago股东的批准。来源烟草在线

　　菲莫国际，拥有75000名员工，运营总部在瑞士洛桑，是奥驰亚剥离了美国业务之外的烟草业务。来源烟草在线

Philip Morris International set to inhale Canadian flu vaccine maker Medicago来源烟草在线

Mon, 2008-09-22 14:50.
By: THE CANADIAN PRESS来源烟草在线

　　QUEBEC - Global cigarette maker Philip Morris International is set to invest $16 million in Canadian vaccine developer Medicago Inc. (TSXV:MDG), taking a 49.9 per cent stake which could grow to a majority holding.来源烟草在线

　　The Quebec City developer of inoculation through virus-like particles said Monday the proceeds of the private placement "will be used to further fund the development of Medicago's pandemic and seasonal influenza vaccines."来源烟草在线

　　Philip Morris International, which last week completed a $2-billion takeover of Canadian tobacco company Rothmans Inc., could increase its holding in Medicago to 58 per cent if all share purchase warrants were exercised.来源烟草在线

　　The massive cigarette company's interest in a small Canadian biotechnology developer is "actually relatively simple," Medicago CEO Andy Sheldon said in an interview.来源烟草在线

　　Philip Morris has "a great deal of expertise in and around tobacco ... agronomics, biotech, genetics and all that stuff," Sheldon said, and at the same time it is moving to diversify away from cigarettes.来源烟草在线

　　Medicago fits with this because it is a pure-play health-care company that uses tobacco "as our machinery, if you will, to produce the different types of vaccines that we're looking at," he said.来源烟草在线

　　"All we do is change the genetic 'program' in tobacco to secrete these proteins."来源烟草在线

　　Under the non-binding letter of intent announced Monday, Philip Morris International is to buy 45 million equity units at 35.5 cents per unit.来源烟草在线

　　The investment demonstrates confidence in the company's proprietary plant-based technology platform, Sheldon stated.来源烟草在线

　　"What we've done is really kind of unique in the world," he added, noting that Medicago has built a production facility and is working toward regulatory vaccine approvals.来源烟草在线

　　"So here's a company that's got expertise in tobacco, which is PMI, and then here's another one, which is Medicago, which has developed some unique Canadian technologies in terms of being able to manufacture vaccines very quickly and very cost-effectively."来源烟草在线

　　The deal is subject to due diligence and Medicago shareholder approval.来源烟草在线

　　Philip Morris International, with 75,000 employees and operational headquarters in Lausanne, Switzerland, is the spun-off Altria Group tobacco business outside the United States.来源烟草在线